Glenjiko

Sustanon 250 steroid: tutto cio che devi sapere Sustanon 250: Una panoramica sullo steroide Cos’e Sustanon 250?

Online Dating Safety and How to Recognize Red Flags

One of the key questions surrounding online dating is whether these platforms lead to long-term relationships. Some 53% of adults under 30 have ever used a dating site or app – including a quarter who have used one in the past year. This compares with 37% of those ages 30 to 49 who have ever […]

Triple negative breast cancer, new therapeutic options and future strategies

Triple negative breast cancer, new therapeutic options and future strategies Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer Triple-negative breast cancer has been viewed as the subtype with the least favorable outcomes for its […]

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67 A neoadjuvant therapy with trastuzumab, pertuzumab and palbociclib reduces tumor proliferation, as shown by a drop in Ki67, in two expansion cohorts of the NA-PHER2 […]

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did […]

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: […]